Positions

Selected Publications

Academic Article

Year Title Altmetric
2019 Radiological imaging and bone marrow biopsy in staging of cutaneous B-cell lymphoma.British Journal of Haematology.  184:674-676. 2019
2018 Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience.Leukemia Research.  75:29-35. 2018
2018 All-trans-retinoic-acid and arsenic trioxide induced remission in promyelocytic blast crisis.Leukemia Research Reports.  10:16-19. 2018
2017 Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia.Leukemia Research Reports.  7:36-39. 2017
2017 Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib.Case Reports in Hematology.  2017:9681832. 2017
2016 VEGF inhibitors in renal cell carcinoma.Clinical Advances in Hematology and Oncology.  14:1016-1028. 2016
2016 Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML.Case Reports in Hematology.  2016:1259759. 2016
2016 Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date.OncoTargets and Therapy.  9:5855-5866. 2016
2014 Remission of rheumatoid arthritis on brentuximab vedotin.Rheumatology.  53:2314-2315. 2014
2014 Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.Physiological Genomics.  46:448-456. 2014
2014 Isolated gastric myeloid sarcoma: a case report and review of the literature.Case Reports in Hematology.  2014:541807. 2014
2011 Obesity and low vision as a result of excessive Internet use and television viewing.International Journal of Food Sciences and Nutrition.  62:60-62. 2011
2010 Do excessive internet use, television viewing and poor lifestyle habits affect low vision in school children?Journal of Child Health Care.  14:375-385. 2010
Treatment of Relapsed/Refractory Acute Myeloid Leukemia.Current Treatment Options in Oncology.  18:17.

Chapter

Year Title Altmetric
2014 Can we cure CML without transplantation?.  279-326. 2014

Research Overview

  • Dr Vachhani’s primary interest is in hematological malignancies, particularly acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN). His specific research interests include developmental therapeutics and clinical trials for high-risk, elderly and relapsed AML.
  • Investigator On

  • Private Grant  awarded by RHIZEN PHARMACEUTICALS SA 2018 - 2023
  • Private Grant  awarded by INCYTE CORPORATION 2016 - 2021
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2017
  • Education And Training

  • Doctor of Medicine, Institution Not Available in List
  • Full Name

  • Pankit Vachhani